Understand the source comparison
Best Peptides for Testosterone Support Research: Comparison
CJC-1295 with DAC GHRH receptor agonist with albumin binding 2mg weekly subcutaneous 8 days Indirect. Restores pulsatile GH → LH normalisation → testosterone synthesis Extended half-life allows weekly dosing; preserves natural GH pulsatility Strongest evidence
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- CJC-1295 with DAC
- GHRH receptor agonist with albumin binding
- 2mg weekly subcutaneous
- 8 days
- Indirect. Restores pulsatile GH → LH normalisation → testosterone synthesis
- Extended half-life allows weekly dosing; preserves natural GH pulsatility
- Strongest evidence for sustained HPG axis restoration; ideal for long-term research protocols
- Ipamorelin
- Selective ghrelin receptor agonist (GHS-R1a)
- 200–300mcg daily subcutaneous
- 2 hours
- Indirect. Stimulates GH pulses without cortisol elevation → LH frequency increase
- Selectivity avoids ACTH cross-reactivity and cortisol spikes that suppress testosterone
- Best option for research requiring daily dosing without adrenal axis interference
- Tesamorelin
- Modified GHRH analogue
- 2mg daily subcutaneous
- 26–38 minutes
- Indirect. GH elevation plus visceral fat reduction (reduces aromatase substrate)
- Dual mechanism: axis stimulation + reduction of testosterone-to-oestradiol conversion
- Optimal for metabolic research where visceral adiposity confounds androgen signalling
- MK-677 (Ibutamoren)
- Oral ghrelin receptor agonist
- 25mg daily oral
- 24 hours
- Indirect. Continuous GH elevation may flatten pulsatile pattern
- Oral bioavailability eliminates injections; sustained 24-hour GH release
- Convenience advantage but loses pulsatile signalling; may be suboptimal for HPG axis research